PHVS
Pharvaris Nv
NASDAQ · Pharmaceuticals
$26.42
+1.28 (+5.09%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 601.07M | 622.81M | 541.11M |
| Net Income | 107.25M | 120.49M | 94.92M |
| EPS | — | — | — |
| Profit Margin | 17.8% | 19.4% | 17.5% |
| Rev Growth | +10.0% | +14.9% | +24.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 233.84M | 201.55M | 201.04M |
| Total Equity | 1.12B | 985.27M | 1.01B |
| D/E Ratio | 0.21 | 0.20 | 0.20 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 198.86M | 206.18M | 175.68M |
| Free Cash Flow | 71.76M | 51.92M | 65.95M |